Argenx SE stock (NL0010832176): focus on Vyvgart growth after latest earnings

Argenx SE recently reported new quarterly figures and updated investors on the growth trajectory of its autoimmune drug franchise, especially Vyvgart, while the stock remains volatile on Nasdaq.

Argenx SE is back in focus for many investors after the company presented fresh quarterly results highlighting rapid uptake of its autoimmune therapy Vyvgart and continued cash burn linked to ongoing clinical trials, according to a quarterly earnings release published in early May 2026 on the company’s investor relations website (argenx investor update as of 05/2026).

The biotech group reported higher revenue driven mainly by sales of Vyvgart in generalized myasthenia gravis, while also outlining progress of additional indications in its pipeline, based on details in its latest shareholder letter and accompanying presentation (argenx news section as of 05/2026). Investors continue to weigh this growth against expenses for research, commercialization and potential future launches.

As of: 25.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Argenx SE
• Sector/industry: Biotechnology, autoimmune therapeutics
• Headquarters/country: Breda, Netherlands
• Core markets: United States, Europe, Japan and other international markets
• Key revenue drivers: Vyvgart-based therapies in autoimmune diseases
• Home exchange/listing venue: Nasdaq (ticker: ARGX) and Euronext Brussels
• Trading currency: USD on Nasdaq, EUR on Euronext Brussels

Argenx SE: core business model

Argenx SE is a clinical-stage and commercial-stage biotechnology company focused on autoimmune diseases, with a particular emphasis on conditions mediated by pathogenic immunoglobulin G antibodies. The group’s first commercial product, Vyvgart, is designed to reduce IgG levels and thereby alleviate disease activity in patients with certain neuromuscular disorders, according to company materials released with recent quarterly reports (argenx pipeline overview as of 05/2026).

The company’s business model combines an antibody discovery platform with a focused commercial infrastructure. Argenx aims to identify high-value autoimmune indications, advance them through clinical development and, where commercially attractive, market the products itself in key territories such as the United States and Europe. In other regions, the group often cooperates with partners or licensees to broaden patient access, as outlined in recent corporate presentations (argenx financial information as of 05/2026).

For US investors, Argenx represents a mid- to large-cap biotech name with a primary listing on Nasdaq, where trading volumes and analyst coverage are typically higher than on its European venue. The company’s valuation is closely linked to expectations around sales trajectories in approved indications and probabilities of success for ongoing clinical trials in additional diseases, all of which influence sentiment in the US equity market.

Main revenue and product drivers for Argenx SE

Vyvgart and related formulations are the central revenue pillar for Argenx. The drug has been approved for generalized myasthenia gravis in several regions, and revenue growth in the latest reported quarter was largely attributed to broader physician adoption and geographic expansion, according to the company’s most recent earnings release and slide deck (argenx earnings materials as of 05/2026). Management also highlighted ongoing work on subcutaneous administration and lifecycle management to strengthen the franchise.

Beyond the flagship product, Argenx is investing in a pipeline of additional autoimmune indications where FcRn inhibition could play a role, including hematology and dermatology areas. These pipeline programs do not yet contribute significantly to revenue but require substantial spending on clinical development, which was visible in the latest quarterly operating expense line items disclosed by the company (argenx quarterly report as of 05/2026).

The revenue mix is also influenced by regional dynamics. In the United States, pricing and access negotiations with payers determine how quickly new therapies gain traction. In Europe and Japan, reimbursement frameworks and national approvals can lead to staggered uptake. For Nasdaq-focused investors, understanding how these regional trends play into consolidated revenue growth is crucial for interpreting the company’s latest earnings and guidance comments.

Conclusion

Argenx SE remains a closely watched biotech name because its latest quarterly results confirm robust growth for Vyvgart while underlining sizable investments in research and commercialization. For US investors following the Nasdaq listing, the stock’s appeal is tied to the balance between expanding autoimmune revenue and ongoing cash needs for the pipeline. As with many biotech companies, future share price performance will largely depend on clinical milestones, regulatory outcomes and the ability to translate scientific assets into sustainable, profitable growth over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.